Century Therapeutics (NASDAQ:IPSC) Releases Earnings Results, Beats Expectations By $0.01 EPS

Century Therapeutics (NASDAQ:IPSC) issued its earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01, FiscalAI reports.

Century Therapeutics Price Performance

Shares of IPSC traded down $0.11 during trading hours on Thursday, reaching $1.63. 608,756 shares of the company’s stock traded hands, compared to its average volume of 1,004,740. The firm has a market capitalization of $295.14 million, a price-to-earnings ratio of -1.75 and a beta of 1.78. Century Therapeutics has a twelve month low of $0.43 and a twelve month high of $3.04. The business’s fifty day simple moving average is $1.65 and its two-hundred day simple moving average is $2.07.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on IPSC. Weiss Ratings restated a “sell (d-)” rating on shares of Century Therapeutics in a research report on Tuesday, September 29th. Wall Street Zen downgraded Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $4.75.

About Century Therapeutics

Century Therapeutics is a biotechnology company developing cell-based therapies for cancer and other serious diseases. Its research focuses on allogeneic treatments, which are designed to be produced from donor cells rather than made separately for each patient. The company uses induced pluripotent stem cell technology to create immune cells, including natural killer cells and T cells, that can be engineered to recognize and attack disease. Its work includes developing cell therapies with genetic modifications intended to improve their activity and persistence.